A Review on Cuminosides Nanomedicine-: Pharmacognostic approach to Cancer therapeutics

As per various reasearch works, Cuminosides isolated from Rhizome of Syzigium cumini has a potential anticancer activity and extensive variety of Antibacterial, antifungal, antioxidative, anti inflamatory activities with absence of toxicity to normal cells of body. Objctives of this review article to clarify enhanced bioavailability and pharmacokinetic properties, acuumlating and absorbing power of this multitargeted drug Cuminosides in nanoformulation at tumor site. Literature survey of cuminoside nanoformulation. talks about its primary rule in viable disease treatment that it destroys particular malignant cells and minimizes there poisonous quality at tumor site. The hemolytic ratio of this formulation is 2.155% which is in the acceptable range for therapeutic applications. Cuminoside nanoformulation also promote uptake of cancer cells in passive targeting due to Enhanced Permeation and Retention” (EPR) effect. Nanocarriers of Cuminoside is made from ethyl cellulose and methylcellulose which readily release cuminoside into blood circulation by adhering to stomach mucousa. This property is responsible for its better anticancer property and it was initially detected using scanning electron microscopy analysis. Cuminoside nanoformulation also reduces effective dose of cisplatin and radiation to inhibit growth of cisplatin resistant ovarian cancer cells. Cuminoside nanoparticles also enhaces tumor reduction of tumor xenografts via dcreased expression of vascular Endothelial Growth Factor (VEGF) as well as COX2. By selectively choosing particle size, zeta potential, stability and targeting moiety, cuminosides nanoformulations can be targeted to specific cancer cells. Cuminosides in form of nanoformulations has numerous advantages including improved efficacy, tumor targeting, reduced systemic toxicity, compliance and convenience. Now a days cuminoside nanoformulation is considred as Abbreviated New Drug Application (ANDA) or New Drug Applications (NDAs).